KyungDong Pharm home
Prescription Medicines

Acepha Inj

Product Category
Antipyretic/analgesic infusion solution
Active Ingredients
Acetaminophen
Appearance
An injection filled with a clear, light yellow, transparent liquid in a colorless, transparent plastic container for intravenous fluids.
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 pack (100mL)
- Active ingredient: Acetaminophen (KP) --- 1g
- Additive (isotonizer): D-mannitol (KP) --- 3.85g
- Additives (antioxidants): L-cysteine hydrochloride monohydrate (USP) --- 25mg
- Additives (buffers): Anhydrous sodium monohydrogen phosphate (USP) --- 10.4mg
- Additive (PH regulator): Sodium hydroxide (KP) --- Appropriate amount
- Additive (PH regulator): Hydrochloric acid (KP) --- Appropriate amount
- Additives (solvent): Water for injection (KP) --- Appropriate amount

2. Effectiveness
When rapid intravenous administration is necessary due to pain or high fever or when administration cannot be administered through other routes
1. Short-term treatment of moderate pain (especially after surgery)
2. Short-term treatment of fever

3. Dosage and dosage
Administered intravenously, limited to adults and children weighing over 33 kg (approximately 11 years of age)
• Adults weighing more than 50kg
1000mg of acetaminophen once, 4 times a day, with an interval of at least 4 hours between administrations.
The maximum daily dose does not exceed 4g.
• Children weighing more than 33kg (about 11 years old), adults weighing less than 50kg
A single dose of acetaminophen is approximately 15 mg/kg (1.5 ml/kg of this drug), and the interval between doses must be at least 4 hours. The maximum daily dose should not exceed 60 mg/kg or 4 g.
• Patients with severe renal impairment
In patients with severe renal impairment (creatinine clearance ≤30ml/min), it is recommended that the administration interval be at least 6 hours.
• Method of administration: This drug is administered as a 15-minute intravenous infusion.

4. Precautions for use
1. Warning
1) Risk of medication error: Medication errors due to confusion between milligrams and milliliters can lead to sudden poisoning or death, so medication must be administered with caution.
2) It is advisable to use appropriate painkillers as soon as oral administration becomes possible.
3) To avoid the risk of overdose, check whether other medications already administered contain acetaminophen.
4) Hepatotoxicity
(1) Doses exceeding the recommended dose may cause very serious liver damage. Clinical symptoms and signs of liver damage are usually first observed 4-6 days later, up to 2 days later. Treat with antidote as quickly as possible.
(2) This drug is sometimes associated with acute liver failure leading to liver transplantation and death, and most liver damage occurs when taken together with other acetaminophen products and exceeds 4,000 milligrams per day, so caution should be exercised when using this drug. In particular, patients with liver impairment must consult with their doctor before taking this medication. When administering high doses exceeding 1,500 milligrams per day for a long period of time, administer with caution, including conducting regular liver function tests.
(3) If a person who regularly drinks three or more glasses of alcohol a day needs to take this medicine or other antipyretic analgesics, he or she must consult a doctor or pharmacist. If these people take this drug, it may cause liver damage.
5) In very rare cases, serious skin reactions such as acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) have been reported in patients taking acetaminophen, and these serious skin reactions can be fatal. Therefore, patients should be fully informed of the signs of such serious skin reactions, and if skin rash or other signs of hypersensitivity appear after taking this drug, they should immediately stop taking it.

2. Do not administer to the following patients
1) Patients with hypersensitivity to acetaminophen, propacetamol hydrochloride, or this drug
2) Peptic ulcer patients
3) Patients with severe blood abnormalities
4) Patients with severe liver impairment
5) Patients with severe renal impairment
6) Patients with severe cardiac dysfunction
7) Patients with aspirin asthma (asthma attacks caused by non-steroidal anti-inflammatory drugs) or a history of it
8) Patients taking the following drugs: barbiturates, tricyclic antidepressants
9) Patients who took alcohol

3. Administer with caution to the following patients:
1) Patients with hepatic impairment or its history
2) Patients with kidney disease or its history
3) Patients with a history of peptic ulcer
4) Patients with blood abnormalities or a history thereof
5) Patients with bleeding tendencies (platelet dysfunction may occur)
6) Patients with cardiac dysfunction
7) Patients with a history of hypersensitivity
8) Patients with bronchial asthma
9) Senior citizens (elderly)
10) Pediatrics
11) Pregnant or lactating women
12) Patients taking warfarin for a long time
13) Patients taking the following drugs: lithium, thiazide diuretics
14) Patients with chronic alcoholism
15) Patients with chronic malnutrition (low liver glutathione reserve)
16) Patients with dehydration and hypovolemia

4. Adverse reactions
Adverse reactions reported in clinical trials are as follows.

*Table: Refer to manual

* Very rare cases of hypersensitivity reactions ranging from simple skin rash or hives to anaphylactic shock have been reported, leading to discontinuation of treatment.
** Frequent adverse reactions (pain, burning) at the injection site were reported during clinical trials.
Overseas post-marketing experience
The following adverse reactions were reported during the post-marketing use results study abroad, and the frequency of occurrence is unknown.

*Table: Refer to manual

Domestic post-marketing survey results
As a result of a post-marketing study conducted on 716 patients over 6 years for re-examination in Korea, the adverse event rate was reported to be 3.91% (28/716, 36 cases) regardless of causal relationship, nausea 1.54% (11/716, 11 cases), vomiting 1.26% (9/716, 9 cases), and headache. 0.84% (6 people/716 people, 6 cases), constipation 0.56% (4 people/716 people, 4 cases), phlegm 0.28% (2 people/716 people, 2 cases), paresthesia, dizziness, decreased hemoglobin, and urination disorder were found to be 0.14% (1 person/716 people, 1 case) respectively. Adverse drug reactions, which are adverse events in which a causal relationship with this drug cannot be ruled out, were reported in 0.70% (5 people/716 people, 6 cases), and nausea and vomiting were reported in 0.42% (3 people/716 people, 3 cases) respectively.
The occurrence rate of unexpected adverse events that occurred during the domestic post-marketing surveillance period was 2.09% (15 people/716 people, 16 cases) regardless of causal relationship, headache 0.84% (6 people/716 people, 6 cases), constipation 0.56% (4 people/716 people, 4 cases), sputum 0.28% (2 people/716 people, 2 cases), paresthesia, Dizziness, decreased hemoglobin, and urination disorder were each found to be 0.14% (1 person/716 people, 1 case).

5. Interaction
1) Probenecid inhibits binding with glucuronic acid, reducing the clearance of acetaminophen by almost two-fold. When used in combination with probenecid, reduce the acetaminophen dose.
2) Salicylamide can prolong the elimination half-life of acetaminophen.
3) Caution must be exercised when using in combination with enzyme-inducing substances.
- It has been reported that co-administration of this drug in long-term users of isoniazid may induce liver enzymes and cause liver failure. Isoniazid induces CYP2E1 and accelerates the metabolism of acetaminophen to N-acetyl-p-benzokinoneimine, which is hepatotoxic.
- It has been reported that blood levels of acetaminophen are reduced in long-term users of carbazepine, phenobarbital, primidone, and rifampicin. It promotes the metabolism of acetaminophen and lowers its blood concentration.
4) Concurrently administered phenytoin may reduce the effect of acetaminophen and increase the risk of hepatotoxicity. Patients receiving phenytoin treatment should avoid taking large doses or long-term use of acetaminophen. Patients should be monitored for hepatotoxicity.
5) Concurrent administration of oral anticoagulants (4 grams per day for at least 4 days) and acetaminophen may cause slight changes in INR (International normalized ratio) values. In these cases, monitoring of INR values ​​should be performed during co-administration and for 1 week after discontinuation of acetaminophen.
6) High anion gap metabolic acidosis (HAGMA) due to pyroglutamine acidosis has been reported in the co-administration of acetaminophen and flucloxacillin. Patients at highest risk are those with underlying diseases such as sepsis, severe renal dysfunction, and malnutrition, and these patients improved after discontinuing one or both drugs. Caution should be exercised when taking this drug and flucloxacillin simultaneously, and if HAGMA is suspected, administration of this drug and/or flucloxacillin should be discontinued.

6. General precautions
1) It has nothing to do with driving or operating machines.
2) This drug should not be mixed with other drugs.
3) Children and the elderly should take the minimum required amount and be careful of adverse reactions. Excessive temperature drop, collapse, and cooling of extremities may occur, so the condition after taking the drug must be carefully monitored, especially in children and the elderly with high fever or patients with consumptive diseases.
4) Since taking this medicine may prevent the infection from appearing on the outside, patients with complications of infection should take an appropriate antibacterial agent according to the doctor's prescription.

7. Administration to pregnant and lactating women
1) Administration to pregnant women: Experience with intravenous administration of acetaminophen is limited. However, demographic data on oral acetaminophen administration showed no undesirable effects on pregnancy or the health of the fetus and newborn.
Reproductive toxicity studies have not been conducted in animals with intravenous acetaminophen, but oral studies have not shown teratogenicity or fetal toxicity.
Nevertheless, this drug should be used during pregnancy after carefully evaluating the benefits and risks. In this case, the recommended dose and administration period should be closely monitored.
2) Administration to nursing mothers: After oral administration, a small amount of acetaminophen was excreted in milk. There have been no reports of adverse reactions in breastfeeding infants.
As a result, this medicine can be used by breastfeeding women.

8. Administration to children
The pharmacokinetic parameters of acetaminophen observed in children are similar to those in adults, except for a slightly shorter plasma half-life (1.5 to 2 hours) than in adults. The plasma half-life in neonates is approximately 3.5 hours, which is longer than in infants. Children up to 10 years of age excrete much less glucuronide conjugates and much more sulfate conjugates than adults. Total excretion of acetaminophen and its metabolites is the same in all age groups.

9. Administration to elderly people
Since the pharmacokinetics and metabolism of acetaminophen do not change in elderly patients, no dose adjustment is necessary.

10. Administration to patients with renal impairment
If the kidneys are severely damaged (creatinine clearance 10 to 30 ml/min), the excretion of acetaminophen is slightly delayed, with an elimination half-life of 2 to 5.3 hours. For glucuron and sulfate conjugates, the rate of excretion is three times slower in patients with severe renal impairment than in healthy subjects. Therefore, in patients with severe renal impairment, it is recommended that administration be administered at least 6 hours apart (creatinine clearance ≤30ml/min).

11. Overdose
In particular, there is a risk of poisoning in the elderly, children, patients with liver disease, chronic alcoholism, chronic malnutrition, and patients receiving enzyme inducers. Poisoning is fatal in these cases.
The following symptoms typically appear within the first 24 hours: nausea, vomiting, loss of appetite, pallor, and lower abdominal pain.
A single overdose of more than 7.5 grams of acetaminophen in adults or 140 mg/kg of body weight in children induces complete irreversible necrosis, causing liver cell destruction, liver cell failure, metabolic acidosis, and brain disease that can lead to coma and death.
At the same time, an increase in liver transaminase (AST, ALT), lactate dehydrogenase, and bilirubin concentrations was observed along with a decrease in prothrombin concentration that could occur 12 to 48 hours after administration.
Clinical symptoms of liver damage became evident after 2 days and reached their maximum after 4 to 6 days.
- First aid
The person should be hospitalized immediately, and before treatment, a fixed-dose acetaminophen antidote should be administered as soon as possible after the overdose. However, N-acetylcysteine ​​(NAC) may provide some protection even after 10 hours, but in these cases treatment may need to be prolonged. Provide symptomatic treatment. Liver tests are performed at the start of treatment and repeated every 24 hours. In most cases, liver transaminases return to normal within 1 to 2 weeks and liver function is fully restored. However, in very rare cases a liver transplant may be necessary.

12. Pharmacological properties
1) Pharmacodynamic properties: The detailed mechanism of the antipyretic and analgesic properties of acetaminophen has not yet been established. It may involve central and peripheral actions. This drug's analgesic effect begins within 5 to 10 minutes after administration. Maximum analgesic effect occurs within 1 hour, and this period lasts approximately 4 to 6 hours. This drug reduces fever within 30 minutes after starting administration and has an antipyretic effect for at least 6 hours.
2) Pharmacokinetic properties (adults)
- Absorption: Acetaminophen shows linear pharmacokinetics up to 2 grams after single administration and repeated administration over 24 hours. The bioavailability of acetaminophen after an injection of 1 gram of this drug is similar to that observed after an injection of 2 grams of propacetamol (containing 1 gram of acetaminophen). The maximum blood concentration (Cmax) of acetaminophen observed upon completion of intravenous administration of 1 gram of this drug for 15 minutes is approximately 30 ㎍/ml.
- Distribution: The distribution volume of acetaminophen is approximately 1L/kg. Acetaminophen does not bind extensively to plasma proteins. After injecting 1 gram of acetaminophen, a significant concentration of acetaminophen was observed in the cerebrospinal fluid starting about 20 minutes later.
- Metabolism: Acetaminophen is metabolized primarily in the liver through two major hepatic pathways: glucuronic acid conjugation and sulfate conjugation, with the sulfate conjugation rapidly saturating at supratherapeutic doses. A small amount (less than 4%) is metabolized by cytochrome P450 into a reactive intermediate (N-acetyl benzoquinone imine), which is quickly detoxified by reduced glutathione under normal conditions and excreted in urine after combining with cysteine ​​and mercapturic acid. However, in cases of massive intoxication, the amount of this toxic metabolite increases.
- Excretion: Metabolites of acetaminophen are mainly excreted in urine. 90% of the administered dose is excreted after 24 hours, mainly as glucuron conjugates (60-80%) and sulfate conjugates. Less than 5% is excreted as is. The plasma half-life is 2.7 hours and the total body clearance is 18 L/h.

13. Precautions for storage and handling
1) Do not store above 30 degrees.
2) Do not refrigerate or freeze.
3) It must be stored in external packaging.
4) Before administration, foreign matter and discoloration inspection must be performed with the naked eye. It should be used only once, and any unused solution should be discarded.

5. How to save
Sealed container, stored at room temperature (1~30℃)

6. Packaging unit
100mL/bag

7. Period of use
24 months from date of manufacture

Product Updates

Total 1items

No.Product NameDetailsDate of ChangeDownload
1Acepha InjPrecautions for use2025.11.10PDFPrecautions for using Acepaju.pdf